Evolution of synchronous female bilateral breast cancers and response to treatment

Archive ouverte

Hamy, Anne-Sophie | Abécassis, Judith | Driouch, Keltouma | Darrigues, Lauren | Vandenbogaert, Mathias | Laurent, Cecile | Zaccarini, Francois | Sadacca, Benjamin | Delomenie, Myriam | Laas, Enora | Mariani, Odette | Lam, Thanh | Grandal, Beatriz | Laé, Marick | Bieche, Ivan | Vacher, Sophie | Pierga, Jean-Yves | Brain, Etienne | Vallot, Celine | Hotton, Judicael | Richer, Wilfrid | Rocha, Dario | Tariq, Zakia | Becette, Veronique | Meseure, Didier | Lesage, Laetitia | Vincent-Salomon, Anne | Filmann, Natalie | Furlanetto, Jenny | Loibl, Sibylle | Dumas, Elise | Waterfall, Joshua | Reyal, Fabien

Edité par CCSD ; Nature Publishing Group -

International audience. Synchronous bilateral breast cancer (sBBC) occurs after both breasts have been affected by the same germline genetics and environmental exposures. Little evidence exists regarding immune infiltration and response to treatment in sBBCs. Here we show that the impact of the subtype of breast cancer on levels of tumor infiltrating lymphocytes (TILs, n = 277) and on pathologic complete response (pCR) rates ( n = 140) differed according to the concordant or discordant subtype of breast cancer of the contralateral tumor: luminal breast tumors with a discordant contralateral tumor had higher TIL levels and higher pCR rates than those with a concordant contralateral tumor. Tumor sequencing revealed that left and right tumors ( n = 20) were independent regarding somatic mutations, copy number alterations and clonal phylogeny, whereas primary tumor and residual disease were closely related both from the somatic mutation and from the transcriptomic point of view. Our study indicates that tumor-intrinsic characteristics may have a role in the association of tumor immunity and pCR and demonstrates that the characteristics of the contralateral tumor are also associated with immune infiltration and response to treatment.

Consulter en ligne

Suggestions

Du même auteur

PD-L1 Expression after Neoadjuvant Chemotherapy in Triple-Negative Breast Cancers Is Associated with Aggressive Residual Disease, Suggesting a Potential for Immunotherapy

Archive ouverte | Grandal, Beatriz | CCSD

International audience. The consequences of neoadjuvant chemotherapy (NAC) for PD-L1 activity in triple-negative breast cancers (TNBC) are not well-understood. This is an important issue as PD-LI might act as a biom...

The Influence of treatment intervals on prognosis in young breast cancer patients: Insights from the French national cohort

Archive ouverte | Laas, Enora | CCSD

International audience. Background: Suboptimal treatment delays is known to impact prognosis of patients with cancer but optimal timing in specific subgroups remains poorly studied. This study aimed to analyze treat...

Identification of Factors Predicting Sensitivity or Resistance to Neoadjuvant Chemotherapy in Breast Cancer. Identification des facteurs prédictifs de sensibilité ou résistance à la chimiothérapie néoadjuvante dans le cancer du sein

Archive ouverte | Hamy, Anne-Sophie | CCSD

Neoadjuvant chemotherapy (NAC i.e. chemotherapy before surgery) is increasingly being used for aggressive or locally advanced breast cancer (BCs). Beyond clinical benefits, it represents an opportunity to monitor in vivo sensitivi...

Chargement des enrichissements...